Alpelisib

ArtNr	HY-15244-10mM
Hersteller	MedChem Express
CAS-Nr.	1217486-61-7
Menge	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Breast Cancer Bone Cancer
Typ	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8.\|[2]Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29.\|[3]Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96. Am J Cancer Res. 2021 Mar 1;11(3):773-792.\|Biochem Biophys Res Commun. 2020 Sep 24;530(3):520-526.\|Biomaterials. 16 September 2022.\|Biomed Pharmacother. 2020 Sep;129:110397.\|Biomed Rep. 2023 Oct 13.\|Biomolecules. 2021 Jan 25;11(2):150.\|bioRxiv. 2020 Jan.\|bioRxiv. 2023 Aug 22.\|bioRxiv. 2023 May 30.\|bioRxiv. 2024 August 18.\|bioRxiv. 2024 July 07.\|bioRxiv. 2024 November 03.\|Biosci Rep. 2020 Oct 30;40(10):BSR20201128.\|Blood. 2019 Jan 3;133(1):70-80.\|Blood. 2024 Jul 5:blood.2023021705.\|Br J Cancer. 2022 Nov 1.\|Br J Haematol. 2020 May;189(4):731-744.\|Breast Cancer Res. 2021 May 21;23(1):57.\|Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12.\|Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.\|Cancer Discov. 2020 Aug;10(8):1226-1239.\|Cancer Discov. 2023 Aug 25;CD-23-0396.\|Cancer Lett. 2019 Jan;440-441:54-63.\|Cancer Lett. 2024 Aug 10.\|Cancer Lett. 2024 Sep 5:217219.\|Cancer Metab. 2025 Feb 7;13(1):6.\|Cancer Nanotechnol. 2023 Mar 29.\|Cancer Res. 2021 Mar 8;canres.3232.2020.\|Cancers (Basel). 2022, 14(15), 3559.\|Cell Biosci. 2022 Dec 30;12(1):210.\|Cell Death Dis. 2020 Oct 6;11(10):831.\|Cell Death Dis. 2022 Jan 12;13(1):54.\|Cell Death Dis. 2023 Dec 14;14(12):831.\|Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.\|Cell Rep. 2020 Sep 29;32(13):108196.\|Cell Rep. 2023 Dec 26;42(12):113535.\|Cell Rep. 2024 Apr 23;43(4):114088.\|Cell Rep. 2024 May 2;43(5):114174.\|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Cell Syst. 2019 Jul 24;9(1):35-48.e5. \|Cell Syst. 2020 Jan 22;10(1):66-81.e11.\|Cells. 2022, 11(15), 2402.\|Diabetes. 2024 Sep 12:db240402.\|Endocrinology. 2023 Sep 13;bqad135.\|Front Oncol. 2021 Jul 13;11:704042.\|Front Oncol. 2021 Nov 24:11:766298.\|Gynecol Oncol. 2020 Dec;159(3):827-838.\|Harvard Medical School LINCS LIBRARY\|Int J Cancer. 2024 Jul 15;155(2):324-338.\|Int J Mol Sci. 2023 Aug 30, 24(17), 13418.\|Int J Mol Sci. 2019 Jul 10;20(14):3383. \|Int J Oncol. 2022 Apr;60(4):37.\|J Anal Sci Technol. 13, 31 (2022).\|J Clin Invest. 2021 Dec 15;131(24):e140436.\|J Exp Med. 2023 Nov 6;220(11):e20211743.\|J Exp Med. 2023 Nov 6;220(11):e20230926.\|J Hematol Oncol. 2020 Feb 22;13(1):13.\|J Med Chem. 2024 Aug 19.\|J Proteome Res. 2021 Apr 26.\|J Transl Med. 2022 Jun 7;20(1):263.\|JCI Insight. 2022 Jul 19;e155899.\|Mol Cancer Res. 2020 Jun;18(6):822-834.\|Mol Psychiatry. 2021 Apr 30.\|Molecules. 2020 Apr 23;25(8):1980.\|Nat Aging. 2023 Jan 23.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Commun. 2020 Aug 13;11(1):4053.\|Nat Commun. 2022 Jan 11;13(1):245.\|Nat Commun. 2023 Jul 13;14(1):4084.\|Nature Cancer. 2021 Jan;2(1):34-48.\|Nature. 2018 Jun;558(7711):540-546. \|Neoplasia. 2023 Jun 20;43:100913.\|Oncogene. 2016 Jul 7;35(27):3607-12. \|Oncol Rep. 2019 Nov;42(5):2097-2107.\|Patent. US20220249511A1.\|Patent. US20220313694A1.\|PLoS One. 2024 Aug 2;19(8):e0308051.\|Preprints. 2024 Feb 16.\|Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2215621119.\|Research Square Preprint. 2020 Aug.\|Research Square Preprint. 2022 Jan.\|Research Square Preprint. 2023 May 10.\|Research Square Preprint. 2023 May 9.\|RSC Adv. 2024 Oct 18;14(45):32876-32882.\|Sci Adv. 2022 Dec 9;8(49):eade7823.\|Sci Rep. 2021 Jan 11;11(1):291.\|Sci Rep. 2025 Jan 18;15(1):2415.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sci Transl Med. 2021 Oct 6;13(614):eabg0809.\|Science. 2017 Dec 1;358(6367):eaan4368.\|Science. 2021 Oct;374(6563):eabf3067.\|Signal Transduct Target Ther. 2024 Jun 17.\|STAR Protoc. 2023 Nov 16;4(4):102683.\|Ther Adv Med Oncol. 2020 Dec 14;12:1758835920975621.\|University of Cologne. 2024.\|Cancers (Basel). 2022, 14(1), 214.
Smiles	CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BYL-719
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	PI3K
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	441.47
Product Description	Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 83.33 mg/mL (ultrasonic)
Manufacturer - Pathway	PI3K/Akt/mTOR
Isoform	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15244-10mM-safety-datasheet.pdf